-
Amantadine and phenytoin: patent protected cases of drug repositioning
Jan M. Keppel Hesselink
Research Article: Clinical Investigation
-
Amantadine and phenytoin: patent protected cases of drug repositioning
Jan M. Keppel Hesselink
Research Article: Clinical Investigation
-
Amantadine and phenytoin: patent protected cases of drug repositioning
Jan M. Keppel Hesselink
Research Article: Clinical Investigation
-
Amantadine and phenytoin: patent protected cases of drug repositioning
Jan M. Keppel Hesselink
Research Article: Clinical Investigation
-
Amantadine and phenytoin: patent protected cases of drug repositioning
Jan M. Keppel Hesselink
Research Article: Clinical Investigation
-
Amantadine and phenytoin: patent protected cases of drug repositioning
Jan M. Keppel Hesselink
Research Article: Clinical Investigation
-
Amantadine and phenytoin: patent protected cases of drug repositioning
Jan M. Keppel Hesselink
Research Article: Clinical Investigation
-
Amantadine and phenytoin: patent protected cases of drug repositioning
Jan M. Keppel Hesselink
Research Article: Clinical Investigation
-
News: Amendment to UK Patent Act provides further exception to patent infringement
News and Views: Clinical Investigation
-
News: Amendment to UK Patent Act provides further exception to patent infringement
News and Views: Clinical Investigation
-
News: Amendment to UK Patent Act provides further exception to patent infringement
News and Views: Clinical Investigation
-
News: Amendment to UK Patent Act provides further exception to patent infringement
News and Views: Clinical Investigation
-
News: Amendment to UK Patent Act provides further exception to patent infringement
News and Views: Clinical Investigation
-
News: Amendment to UK Patent Act provides further exception to patent infringement
News and Views: Clinical Investigation
-
News: Amendment to UK Patent Act provides further exception to patent infringement
News and Views: Clinical Investigation
-
News: Amendment to UK Patent Act provides further exception to patent infringement
News and Views: Clinical Investigation
-
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Aaron R Hansen, Albiruni RA Razak
Editorial: Clinical Investigation
-
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Aaron R Hansen, Albiruni RA Razak
Editorial: Clinical Investigation
-
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Aaron R Hansen, Albiruni RA Razak
Editorial: Clinical Investigation
-
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Aaron R Hansen, Albiruni RA Razak
Editorial: Clinical Investigation
-
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Aaron R Hansen, Albiruni RA Razak
Editorial: Clinical Investigation
-
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Aaron R Hansen, Albiruni RA Razak
Editorial: Clinical Investigation
-
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Aaron R Hansen, Albiruni RA Razak
Editorial: Clinical Investigation
-
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Aaron R Hansen, Albiruni RA Razak
Editorial: Clinical Investigation
-
Personalized medicine in non-smallcell lung cancer: has it come of age?
Martin Sebastian, Martin Reck
Editorial: Clinical Investigation
-
Personalized medicine in non-smallcell lung cancer: has it come of age?
Martin Sebastian, Martin Reck
Editorial: Clinical Investigation
-
Personalized medicine in non-smallcell lung cancer: has it come of age?
Martin Sebastian, Martin Reck
Editorial: Clinical Investigation
-
Personalized medicine in non-smallcell lung cancer: has it come of age?
Martin Sebastian, Martin Reck
Editorial: Clinical Investigation
-
Personalized medicine in non-smallcell lung cancer: has it come of age?
Martin Sebastian, Martin Reck
Editorial: Clinical Investigation
-
Personalized medicine in non-smallcell lung cancer: has it come of age?
Martin Sebastian, Martin Reck
Editorial: Clinical Investigation
-
Personalized medicine in non-smallcell lung cancer: has it come of age?
Martin Sebastian, Martin Reck
Editorial: Clinical Investigation
-
Personalized medicine in non-smallcell lung cancer: has it come of age?
Martin Sebastian, Martin Reck
Editorial: Clinical Investigation
-
Early-phase oncology clinical trial design in the era of molecularly targeted therapy: pitfalls and progress
Penelope Bradbury, John Hilton , Lesley Seymour
Review Article: Clinical Investigation
-
Early-phase oncology clinical trial design in the era of molecularly targeted therapy: pitfalls and progress
Penelope Bradbury, John Hilton , Lesley Seymour
Review Article: Clinical Investigation
-
Early-phase oncology clinical trial design in the era of molecularly targeted therapy: pitfalls and progress
Penelope Bradbury, John Hilton , Lesley Seymour
Review Article: Clinical Investigation
-
Early-phase oncology clinical trial design in the era of molecularly targeted therapy: pitfalls and progress
Penelope Bradbury, John Hilton , Lesley Seymour
Review Article: Clinical Investigation
-
Early-phase oncology clinical trial design in the era of molecularly targeted therapy: pitfalls and progress
Penelope Bradbury, John Hilton , Lesley Seymour
Review Article: Clinical Investigation
-
Early-phase oncology clinical trial design in the era of molecularly targeted therapy: pitfalls and progress
Penelope Bradbury, John Hilton , Lesley Seymour
Review Article: Clinical Investigation
-
Early-phase oncology clinical trial design in the era of molecularly targeted therapy: pitfalls and progress
Penelope Bradbury, John Hilton , Lesley Seymour
Review Article: Clinical Investigation
-
Early-phase oncology clinical trial design in the era of molecularly targeted therapy: pitfalls and progress
Penelope Bradbury, John Hilton , Lesley Seymour
Review Article: Clinical Investigation
-
Emerging therapies in the management of hypertensive patients with osteoarthritis
Giorgio Gentile, Fabio Angeli, Giovanni Mazzotta, Gianpaolo Reboldi , Paolo Verdecchia
Review Article: Clinical Investigation
-
Emerging therapies in the management of hypertensive patients with osteoarthritis
Giorgio Gentile, Fabio Angeli, Giovanni Mazzotta, Gianpaolo Reboldi , Paolo Verdecchia
Review Article: Clinical Investigation
-
Emerging therapies in the management of hypertensive patients with osteoarthritis
Giorgio Gentile, Fabio Angeli, Giovanni Mazzotta, Gianpaolo Reboldi , Paolo Verdecchia
Review Article: Clinical Investigation
-
Emerging therapies in the management of hypertensive patients with osteoarthritis
Giorgio Gentile, Fabio Angeli, Giovanni Mazzotta, Gianpaolo Reboldi , Paolo Verdecchia
Review Article: Clinical Investigation
-
Emerging therapies in the management of hypertensive patients with osteoarthritis
Giorgio Gentile, Fabio Angeli, Giovanni Mazzotta, Gianpaolo Reboldi , Paolo Verdecchia
Review Article: Clinical Investigation
-
Emerging therapies in the management of hypertensive patients with osteoarthritis
Giorgio Gentile, Fabio Angeli, Giovanni Mazzotta, Gianpaolo Reboldi , Paolo Verdecchia
Review Article: Clinical Investigation
-
Emerging therapies in the management of hypertensive patients with osteoarthritis
Giorgio Gentile, Fabio Angeli, Giovanni Mazzotta, Gianpaolo Reboldi , Paolo Verdecchia
Review Article: Clinical Investigation
-
Emerging therapies in the management of hypertensive patients with osteoarthritis
Giorgio Gentile, Fabio Angeli, Giovanni Mazzotta, Gianpaolo Reboldi , Paolo Verdecchia
Review Article: Clinical Investigation